Cabaletta Bio, Inc. (CABA) News
Follow Cabaletta Bio, Inc. (CABA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 9 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
CABA’s reсе-cel touts nine-day manufacturing and strong safety profile
Rese-cel’s nine-day manufacturing process and strong safety profile are highlighted in CAR-T for autoimmune diseases, with over 90 patients treated and no severe neurotoxicity or IEC-HS events.
EQUITY | Sep 09, 2026, 03:10 PM UTC
L
CABA Rese-cel CAR-T data highlights safety and scalable manufacturing
Rese-cel’s nine-day CAR-T process reported strong safety and efficacy in autoimmune diseases, with over 90 patients treated and no IEC-HS events. Dual-source manufacturing and outpatient protocols are part of the scale-u
EQUITY | Sep 09, 2026, 02:59 PM UTC
M
CABA highlights rese-cel CAR-T safety and nine-day manufacturing process
Cabaletta’s rese-cel team cited a nine-day manufacturing process and strong safety profile, reporting over 90 patients treated with no IEC-HS events. Expansion into scleroderma and myositis is underway with dual manufact
EQUITY | Sep 09, 2026, 01:52 PM UTC
L
BlackRock Group files Form 8.3 for CAB Payments Holdings plc
BlackRock Group filed a Form 8.3 public opening position disclosure/dealing disclosure for CAB Payments Holdings plc under Rule 8.3 of the Takeover Code.
MNA | Sep 08, 2026, 02:20 PM UTC
L
BlackRock Group files Form 8.3 disclosure for CAB Payments Holdings plc
BlackRock Group has filed a Form 8.3 public opening position disclosure/dealing disclosure as required under Rule 8.3 of the Takeover Code for CAB Payments Holdings plc.
MNA | Sep 04, 2026, 02:20 PM UTC
L
BlackRock Group files Form 8.3 for CAB Payments Holdings plc
BlackRock Group disclosed a public opening position under Rule 8.3 for CAB Payments Holdings plc via Form 8.3 dealing disclosure.
MNA | Sep 03, 2026, 02:20 PM UTC
L
HC Wainwright maintains Cabaletta Bio price target at $16.00
HC Wainwright & Co. maintained its price target on Cabaletta Bio at $16.00 per share, according to Benzinga ratings actions.
EQUITY | Sep 01, 2026, 05:26 PM UTC
L
Cabaletta Bio to participate in upcoming investor conferences
Cabaletta Bio, Inc. said it will participate in upcoming investor conferences.
EQUITY | Sep 01, 2026, 12:07 PM UTC
L
Cabaletta Bio (CABA) reports Q2 2026 financial results, business update
Cabaletta Bio reports its second-quarter 2026 financial results and provides a business update, according to TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 11:30 AM UTC